Existence of Leukemic Clones Resistant to Both Imatinib Mesylate and Rituximab before Drug Therapies in a Patient with Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia-Reference-Cited by-同舟云学术

Existence of Leukemic Clones Resistant to Both Imatinib Mesylate and Rituximab before Drug Therapies in a Patient with Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Published:2004-07-01 Issue:1 Volume:80 Page:62-66
ISSN:0925-5710
Container-title:International Journal of Hematology
language:
Short-container-title:International Journal of Hematology

Author:

Hato Takaaki,Yamanouchi Jun,Tamura Tatsushiro,Hojo Norimasa,Niiya Yasunari,Kohno Masashi,Bando Shiro,Yakushijin Yoshihiro,Takada Kiyonori,Sakai Ikuya,Yasukawa Masaki,Fujita Shigeru

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://www.springerlink.com/index/pdf/10.1532/IJH97.04033

Reference30 articles.

1. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.

2. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349: 1423-1432.

3. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.

4. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100: 1965-1971.

5. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472-3475.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD20, generalidades básicas-moleculares y su posible relación como marcador de mal pronóstico en leucemia;Revista Colombiana de Cancerología;2023-03-30

2. Primary central nervous system CD20-negative diffuse large B-cell lymphoma: a case report;BMC Neurology;2022-12-29

3. Immunotherapies: Exploiting the Immune System for Cancer Treatment;Journal of Immunology Research;2018

4. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan;Journal of Hematology & Oncology;2017-02-23

5. Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma;Biochemical and Biophysical Research Communications;2016-05